Analgesic Ear Drops for Children With Acute Otitis Media

Last updated: May 9, 2024
Sponsor: UMC Utrecht
Overall Status: Terminated

Phase

3

Condition

Pain

Otitis Media

Ear Infections (Pediatric)

Treatment

lidocaine hydrochloride 5mg/g

Clinical Study ID

NCT05651633
80-87200-98-1017
10060011910003
NL9500
2021-003019-24
  • Ages 1-6
  • All Genders

Study Summary

This trial aims to investigate whether analgesic ear drops added to usual care provide superior ear pain relief over usual care alone in children presenting to primary care with AOM. Children will be randomly allocated (ratio 1:1) to either 1) lidocaine hydrochloride 5mg/g ear drops (Otalgan) 1-2 drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics) or 2) usual care. Parents will complete a symptom diary for 4 weeks as well as generic and disease-specific quality of life questionnaires at baseline and 4 weeks. The primary outcome is the parent-reported ear pain score (0-10) over the first 3 days.

NOTE:

At the time of publication of the study protocol paper, the investigators were unable to make any amendments to the trial registration record in the Netherlands Trial Register (NTR) (NL9500; date of registration: 28 May 2021). The addition of a data sharing plan was required to adhere to the International Committee of Medical Journal Editors (ICMJE) guidelines. The investigators therefore re-registered the trial in ClinicalTrials.gov. This second registration is for modification purposes only and the NTR record (NL9500) should be regarded as the primary trial registration.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 1 to 6 years

  • Parent-reported ear pain in 24 hours prior to enrolment

  • GP-diagnosis of (uni- or bilateral) AOM

Exclusion

Exclusion Criteria:

  • with (suspected) tympanic membrane perforation or ventilation tubes

  • with ear wax obscuring visualisation of the tympanic membrane

  • who are systemically very unwell or require hospital admission (e.g. child has signsand symptoms of serious illness and/or complications such as mastoiditis/meningitis)

  • who are at high risk of serious complications including children with knownimmunodeficiency other than partial IgA or IgG2 deficiencies, craniofacialmalformation including cleft palate, Down syndrome and previous ear surgery (withthe exception of ventilation tubes in the past)

  • who have a known allergy or sensitivity to study medication or similar substances (e.g. other amide-type anaesthetics: bupivacaine, mepivacaine, prilocaine, etc)

  • who have taken part in any research involving medicines within the last 90 days, orany other AOM-related research within the last 30 days

  • who suffer from chronic recurrent pain of another origin than the ear

  • who have participated in this trial during prior AOM episode

Study Design

Total Participants: 29
Treatment Group(s): 1
Primary Treatment: lidocaine hydrochloride 5mg/g
Phase: 3
Study Start date:
October 06, 2021
Estimated Completion Date:
January 10, 2024

Connect with a study center

  • University Medical Center Utrecht

    Utrecht, 3584 CX
    Netherlands

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.